CSIMarket
 


Verastem inc   (VSTM)
Other Ticker:  
 
 

VSTM's Income from Cont. Operations Growth by Quarter and Year

Verastem Inc 's Income from Cont. Operations results by quarter and year




VSTM Income from Cont. Operations (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December -27.37 -16.81 -16.48 -19.86
III Quarter September -20.00 -18.09 -22.79 13.14
II Quarter June -24.28 -21.95 -16.90 -23.01
I Quarter March -15.71 -16.96 -15.03 -37.99
FY   -87.36 -73.81 -71.20 -67.72



VSTM Income from Cont. Operations fourth quarter 2023 Y/Y Growth Comment
Verastem inc in the fourth quarter 2023 recorded loss from continued operations of $ -27.37 millions.

According to the results reported in the fourth quarter 2023, Verastem Inc achieved the best Income from Cont. Operations growth in Major Pharmaceutical Preparations industry. While Verastem Inc ' s Income from Cont. Operations no change of % ranks overall at the positon no. in the fourth quarter 2023.




VSTM Income from Cont. Operations ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Verastem Inc 's fourth quarter 2023 Income from Cont. Operations $ -27.37 millions VSTM's Income Statement
Verastem Inc 's fourth quarter 2022 Income from Cont. Operations $ -16.81 millions Quarterly VSTM's Income Statement
New: More VSTM's historic Income from Cont. Operations Growth >>


VSTM Income from Cont. Operations (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Verastem Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


VSTM's IV. Quarter Q/Q Income from Cont. Operations Comment
Current accomplishment of -27.37 millions by Verastem inc appear even worse if you take a look at -20.00 millions loss from continued operations a quarter before.

Within Major Pharmaceutical Preparations industry Verastem inc achieved highest sequential Income from Cont. Operations growth. While Verastem Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


VSTM's IV. Quarter Q/Q Income from Cont. Operations Comment
Current accomplishment of -27.37 millions by Verastem inc come out even more unfavourable considering the -20.00 millions loss from continued operations in the third quarter.

Within Major Pharmaceutical Preparations industry Verastem inc achieved highest sequential Income from Cont. Operations growth. While Verastem Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Verastem Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Income from Cont. Operations 12 Months Ending $ -87.37 $ -76.81 $ -74.89 $ -72.56 $ -73.81
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
Verastem Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -87 millions in the Dec 31 2023 period.
The situation is getting worse as the cumulative loss from continued operations is getting bigger from $ -76.81 millions in TTM ending quarter Sep 30 2023 and $ -73.485 millions for the twelve months ending in the quarter Dec 31 2022 Aditya Malhotra  mentioned.

Verastem inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
Verastem Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -87 millions in the Dec 31 2023 period.
The situation is getting worse as the cumulative loss from continued operations is becoming larger from $ -76.81 millions in TTM ending quarter Sep 30 2023 and $ -73.485 millions for the twelve months ending in the quarter a year ago.

Verastem inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Major Pharmaceutical Preparations Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
VSTM's Income from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for VSTM's Competitors
Income from Cont. Operations Growth for Verastem Inc 's Suppliers
Income from Cont. Operations Growth for VSTM's Customers

You may also want to know
VSTM's Annual Growth Rates VSTM's Profitability Ratios VSTM's Asset Turnover Ratio VSTM's Dividend Growth
VSTM's Roe VSTM's Valuation Ratios VSTM's Financial Strength Ratios VSTM's Dividend Payout Ratio
VSTM's Roa VSTM's Inventory Turnover Ratio VSTM's Growth Rates VSTM's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Dec 31 2023
Iqvia Holdings Inc 106.61%$ 106.608 millions
Davita Inc 103.75%$ 103.752 millions
Stryker Corp103.02%$ 103.020 millions
Enzon Pharmaceuticals inc 101.80%$ 101.802 millions
Surgery Partners Inc 100.43%$ 100.429 millions
Corcept Therapeutics Inc88.36%$ 88.364 millions
Intuitive Surgical Inc 81.38%$ 81.378 millions
Astrazeneca Plc81.02%$ 81.020 millions
Tactile Systems Technology Inc 77.49%$ 77.494 millions
Quest Diagnostics Inc76.72%$ 76.724 millions
Dr Reddy s Laboratories Limited76.21%$ 76.206 millions
3m Company74.40%$ 74.401 millions
Electromed Inc 71.34%$ 71.341 millions
Tenet Healthcare Corp66.42%$ 66.423 millions
Alpha Pro Tech Ltd 66.36%$ 66.364 millions
Neurocrine Biosciences Inc 65.96%$ 65.955 millions
Cytek Biosciences Inc 64.76%$ 64.760 millions
United Therapeutics Corporation64.35%$ 64.345 millions
Fonar Corporation64.30%$ 64.296 millions
Select Medical Holdings Corp63.87%$ 63.868 millions
Abbott Laboratories54.31%$ 54.308 millions
Integer Holdings Corporation54.22%$ 54.225 millions
Lemaitre Vascular Inc 50.44%$ 50.435 millions
Encompass Health Corporation49.94%$ 49.941 millions
Msa Safety Incorporated48.40%$ 48.401 millions
Halozyme Therapeutics Inc 47.98%$ 47.981 millions
Cadre Holdings Inc 45.39%$ 45.386 millions
Chemed Corporation44.95%$ 44.952 millions
Viemed Healthcare Inc 42.62%$ 42.617 millions
Healthcare Services Group Inc 39.85%$ 39.848 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com